Literature DB >> 2462255

Galanin antagonizes acetylcholine on a memory task in basal forebrain-lesioned rats.

J Mastropaolo1, N S Nadi, N L Ostrowski, J N Crawley.   

Abstract

Galanin coexists with acetylcholine in medial septal neurons projecting to the ventral hippocampus, a projection thought to modulate memory functions. Neurochemical lesions of the nucleus basalis-medial septal area in rats impaired choice accuracy on a delayed alternation t-maze task. Acetylcholine (7.5 or 10 micrograms intraventricularly or 1 micrograms micro-injected into the ventral hippocampus) significantly improved performance in the lesioned rats. Atropine (5 mg/kg intraperitoneally or 10 micrograms intraventricularly), but not mecamylamine (3 mg/kg intraperitoneally or 20 micrograms intraventricularly), blocked this action of acetylcholine, suggesting involvement of a muscarinic receptor. Galanin (100-500 ng intraventricularly or 200 ng into the ventral hippocampus) attenuated the ability of acetylcholine to reverse the deficit in working memory in the lesioned rats. The antagonistic interaction between galanin and acetylcholine suggests that endogenous galanin may inhibit cholinergic function in memory processes, particularly in pathologies such as Alzheimer disease that involve degeneration of basal forebrain neurons.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462255      PMCID: PMC282877          DOI: 10.1073/pnas.85.24.9841

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Basal forebrain lesions differentially alter galanin levels and acetylcholinergic receptors in the hippocampus and neocortex.

Authors:  G L Wenk; A Rökaeus
Journal:  Brain Res       Date:  1988-09-13       Impact factor: 3.252

2.  Galanin immunoreactivity in human CSF: studies in eating disorders and Alzheimer's disease.

Authors:  W H Berrettini; W H Kaye; T Sunderland; C May; H E Gwirtsman; A Mellow; A Albright
Journal:  Neuropsychobiology       Date:  1988       Impact factor: 2.328

3.  Galanin - a novel biologically active peptide from porcine intestine.

Authors:  K Tatemoto; A Rökaeus; H Jörnvall; T J McDonald; V Mutt
Journal:  FEBS Lett       Date:  1983-11-28       Impact factor: 4.124

4.  Memory retention: potentiation of cholinergic drug combinations in mice.

Authors:  J F Flood; G E Smith; A Cherkin
Journal:  Neurobiol Aging       Date:  1983       Impact factor: 4.673

5.  Memory impairments following basal forebrain lesions.

Authors:  D J Hepler; G L Wenk; B L Cribbs; D S Olton; J T Coyle
Journal:  Brain Res       Date:  1985-10-28       Impact factor: 3.252

6.  Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.

Authors:  J N Crawley; J A Stivers; L K Blumstein; S M Paul
Journal:  J Neurosci       Date:  1985-08       Impact factor: 6.167

7.  Lesioning of the rat basal forebrain leads to memory impairments in passive and active avoidance tasks.

Authors:  M Miyamoto; M Shintani; A Nagaoka; Y Nagawa
Journal:  Brain Res       Date:  1985-02-25       Impact factor: 3.252

8.  Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine.

Authors:  C L Murray; H C Fibiger
Journal:  Neuroscience       Date:  1985-04       Impact factor: 3.590

9.  Impairment in T-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats.

Authors:  J D Salamone; P M Beart; J E Alpert; S D Iversen
Journal:  Behav Brain Res       Date:  1984-07       Impact factor: 3.332

10.  Lesions in nucleus basalis magnocellularis and medial septal area of rats produce qualitatively similar memory impairments.

Authors:  D J Hepler; D S Olton; G L Wenk; J T Coyle
Journal:  J Neurosci       Date:  1985-04       Impact factor: 6.167

View more
  16 in total

1.  Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease.

Authors:  R A Steiner; J G Hohmann; A Holmes; C C Wrenn; G Cadd; A Juréus; D K Clifton; M Luo; M Gutshall; S Y Ma; E J Mufson; J N Crawley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

2.  CSF galanin and cognition after shunt surgery in normal pressure hydrocephalus.

Authors:  M Mataró; M A Poca; M Del Mar Matarín; R Catalan; J Sahuquillo; R Galard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 3.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze.

Authors:  Kathleen R Bailey; Maria N Pavlova; Alex D Rohde; John G Hohmann; Jacqueline N Crawley
Journal:  Pharmacol Biochem Behav       Date:  2007-01-25       Impact factor: 3.533

5.  M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord.

Authors:  T Bartfai; K Bedecs; T Land; U Langel; R Bertorelli; P Girotti; S Consolo; X J Xu; Z Wiesenfeld-Hallin; S Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

6.  N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor.

Authors:  G Fisone; M Berthold; K Bedecs; A Undén; T Bartfai; R Bertorelli; S Consolo; J Crawley; B Martin; S Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 7.  Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease.

Authors:  M P McDonald; J N Crawley
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

8.  Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.

Authors:  A M Mazarati; H Liu; U Soomets; R Sankar; D Shin; H Katsumori; U Langel; C G Wasterlain
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

9.  Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.

Authors:  J J Hagan; J H Jansen; F E Nefkens; T de Boer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Galanin antagonist effects on cardiac vagal inhibitory actions of sympathetic stimulation in anaesthetized cats and dogs.

Authors:  L G Ulman; M Moriarty; E K Potter; D I McCloskey
Journal:  J Physiol       Date:  1993-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.